Tolterodine
Detrol, Tolterodine (tolterodine) is a small molecule pharmaceutical. Tolterodine was first approved as Detrol on 1998-03-25. It is used to treat urinary bladder diseases and urinary incontinence in the USA. It is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M2, and muscarinic acetylcholine receptor M1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Detrol, Tolterodine (discontinued: Tolterodine)
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| detrol | New Drug Application | 2023-02-15 |
| detrol la | New Drug Application | 2023-03-15 |
| tolterodine tartarate tolterodine tartrate | ANDA | 2023-03-23 |
| tolterodine tartrate | ANDA | 2025-02-07 |
| tolterodine tartrate extended release | NDA authorized generic | 2024-12-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urinary incontinence | — | D014549 | R32 |
| urinary bladder diseases | — | D001745 | N32.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 7 | 10 | 21 | 21 | 14 | 71 |
| Urinary incontinence | D014549 | — | R32 | 2 | 2 | 2 | 11 | 3 | 20 |
| Enuresis | D004775 | — | R32 | — | 1 | — | 7 | 3 | 11 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | 1 | — | 3 | 2 | 6 |
| Syndrome | D013577 | — | — | 1 | — | — | 3 | 1 | 5 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | 2 | — | 4 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | 1 | 1 | 1 | 1 | 3 |
| Chronic pain | D059350 | — | — | — | — | — | 2 | — | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 2 | — | 2 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | 2 | — | 2 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Low back pain | D017116 | — | M54.5 | — | — | 1 | — | — | 1 |
| Back pain | D001416 | — | M54 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Nocturnal enuresis | D053206 | — | N39.44 | — | 1 | 1 | — | — | 1 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | — | — | 1 |
| Prolapse | D011391 | — | — | — | — | 1 | — | — | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | — | — | 1 |
| Pelvic pain | D017699 | — | — | — | — | 1 | — | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | — | — | — | 1 | 1 |
| Prostatitis | D011472 | EFO_0003830 | N41 | — | — | — | — | 1 | 1 |
| Cross-sectional studies | D003430 | — | — | — | — | — | — | 1 | 1 |
| Deprescriptions | D000069340 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tolterodine |
| INN | tolterodine |
| Description | Tolterodine is a tertiary amine. It has a role as a muscarinic antagonist, a muscle relaxant and an antispasmodic drug. It is functionally related to a p-cresol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 124937-51-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1382 |
| ChEBI ID | 9622 |
| PubChem CID | 443879 |
| DrugBank | DB01036 |
| UNII ID | WHE7A56U7K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM4
CHRM4
CHRM3
CHRM3
CHRM5
CHRM5
CHRM2
CHRM2
CHRM1
CHRM1
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Detrol – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Tolterodine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,411 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,879 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use